First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

類似資料

• First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
  著者:: Fuchs, JD, 等
  出版事項: (2012)
• Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119
  著者:: Spyros A. Kalams, 等
  出版事項: (2024-09-01)
• Prime-Boost Vaccination with Recombinant Mumps Virus and Recombinant Vesicular Stomatitis Virus Vectors Elicits an Enhanced Human Immunodeficiency Virus Type 1 Gag-Specific Cellular Immune Response in Rhesus Macaques
  著者:: Xu, R., 等
  出版事項: (2009)
• Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial
  著者:: Elizaga, Marnie L., 等
  出版事項: (2018)
• DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8(+) T-Cell Responses by Interleukin-12 Plasmid DNA
  著者:: Li, Shuying S., 等
  出版事項: (2017)